GlassScriptPhysician profile
Mitchell Wayne Sanders
NPI 1528680162
$1,820.61
in general payments reported to CMS, 2019-2025
24 companies · $441 in 2025
The $441 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $305 · 2023: $463 · 2024: $612 · 2025: $441.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,515.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,515.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $463.09 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $263.33 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $176.50 | 2022-2025 | Breztri, Airsupra |
| Novartis Pharmaceuticals Corporation | $127.24 | 2023-2024 | |
| Mylan Specialty L.P. | $116.95 | 2023-2024 | Yupelri |
| Glaxosmithkline, LLC. | $103.63 | 2022-2025 | Arexvy, Shingrix, Bexsero |
| Dexcom, INC. | $87.61 | 2022-2025 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $77.23 | 2022-2025 | Kisunla, Jardiance, Zepbound |
| Boston Scientific Corporation | $70.38 | 2025 | Watchman Access System |
| Otsuka America Pharmaceutical, INC. | $51.49 | 2022-2025 | Rexulti |
| Corcept Therapeutics | $39.40 | 2023 | Korlym |
| Abbott Laboratories | $24.28 | 2025 | Freestyle Libre 3 |
| Viatris Specialty LLC | $22.91 | 2025 | Yupelri |
| Acadia Pharmaceuticals INC | $22.72 | 2025 | Daybue |
| Lundbeck LLC | $21.89 | 2025 | Vyepti |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Seqirus USA INC | $19.63 | 2025 | Flucelvax |
| Biohaven Pharmaceutical Holding Company LTD. | $19.07 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.58 | 2023 | |
| Exact Sciences Corporation | $17.41 | 2025 | Cologuard Collection Kit |
| Amgen INC. | $17.06 | 2024 | Repatha, Otezla |
| Sunovion Pharmaceuticals INC. | $15.84 | 2022 | |
| Vanda Pharmaceuticals INC. | $15.68 | 2024 | Fanapt |
| Sumitomo Pharma America, INC. | $14.86 | 2023 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.83 | 2023 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitchell Sanders listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.